Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02082210
Title A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

hepatocellular carcinoma

Advanced Solid Tumor

renal cell carcinoma

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Emibetuzumab + Ramucirumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.